Product Information
EBGLYSS 250 MG/2 ML PEN is a brand product labeled by Eli Lilly and Company, priced at $1783.5238 per ML under NDC 00002777211. Its NADAC has been published 42 times since Dec 17, 2025.
Strength
250 mg/2mL
Manufacturer
Eli Lilly and CompanyNDC
00002777211
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
LEBRIKIZUMABApproval Type
Biologic (BLA)
FDA Application
BLA761306On Market Since
9/13/2024
Pharmacological Classes
Price Statistics
The NADAC for EBGLYSS 250 MG/2 ML PEN has been published 42 times since Dec 17, 2025, and over the history we have for it it has risen 4.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1783.5238 per ML |
|---|---|
| All-time high | $1795.8056 (Jun 10, 2026) |
| All-time low | $1710.2910 (Dec 17, 2025) |
| 52-week high | $1795.8056 |
| 52-week low | $1710.2910 |
| Median price | $1795.8056 |
| Average price | $1783.5269 |
| Largest weekly change | +5.0% (Jan 14, 2026) |
| Weeks tracked | 42 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the lebrikizumab-lbkz market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lebrikizumab-lbkz market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EBGLYSS 250 MG/2 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for EBGLYSS 250 MG/2 ML PEN, manufactured by Eli Lilly and Company, is $1783.5238 per ML (NDC 00002777211), effective Sep 30, 2026.
How has the price of EBGLYSS 250 MG/2 ML PEN changed over time?
Over the history we have for it, the NADAC for EBGLYSS 250 MG/2 ML PEN has risen 4.3%. It has been tracked across 42 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for EBGLYSS 250 MG/2 ML PEN?
Since Dec 17, 2025, the NADAC for EBGLYSS 250 MG/2 ML PEN has ranged from a low of $1710.2910 (Dec 17, 2025) to a high of $1795.8056 (Jun 10, 2026), with a median of $1795.8056 per ML.
Are there cheaper alternatives to EBGLYSS 250 MG/2 ML PEN?
No other NADAC-published product currently shares the active ingredient and strength of EBGLYSS 250 MG/2 ML PEN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EBGLYSS 250 MG/2 ML PEN?
EBGLYSS 250 MG/2 ML PEN (NDC 00002777211) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.